Insights

Strategic funding ORCOSA is a clinical-stage biotech with ongoing funding and leadership expansion, including a new CFO appointment in 2026. This indicates available budget for partnership programs, grant-ready collaborations, and co-development or supply agreements tied to its RITe Platform and ORAVEXX product candidate.

Clinical collaboration The company actively supports FDA-authorized investigator-initiated trials leveraging the RITe Platform, presenting multiple entry points for research partnerships, sponsored trials, and early-access programs that could be monetized through contract research services or licensing opportunities.

Executive network Recent additions to the leadership team and board, including a CFO and experienced medical officer, broaden access to financial and regulatory channels. This enhances credibility for strategic alliances, large-scale funding rounds, and negotiations with contract manufacturers and clinical partners.

Manufacturing readiness With a state-of-the-art cGMP-compliant U.S. facility and proprietary manufacturing processes, ORCOSA can offer scalable production for potential partners seeking CBD-based or rapid-delivery therapeutics, enabling co-development or toll manufacturing arrangements.

Pain management focus The ORAVEXX CBD composition targets pain management and opioid-sparing treatment, aligning with growing market demand for non-addictive analgesics. This position makes ORCOSA a candidate for collaborations with pharmaceutical, biotech, and healthcare distributors seeking safer pain therapies.

Similar companies to ORCOSA Inc

ORCOSA Inc Tech Stack

ORCOSA Inc uses 8 technology products and services including Sucuri, Open Graph, WordPress, and more. Explore ORCOSA Inc's tech stack below.

Media & News

ORCOSA Inc's Email Address Formats

ORCOSA Inc uses at least 1 email format:
ORCOSA Inc Email FormatsExamplePercentage
FLast@orcosa.comJDoe@orcosa.com
100%

Frequently Asked Questions

What is ORCOSA Inc's official website and social media links?

Minus sign iconPlus sign icon
ORCOSA Inc's official website is orcosa.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does ORCOSA Inc generate?

Minus sign iconPlus sign icon
As of November 2026, ORCOSA Inc's annual revenue is estimated to be $1M - $10M.

What is ORCOSA Inc's SIC code and NAICS code?

Minus sign iconPlus sign icon
ORCOSA Inc's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does ORCOSA Inc have currently?

Minus sign iconPlus sign icon
As of November 2026, ORCOSA Inc has approximately 12 employees across 1 continents, including North America. Key team members include Tecnico: A. C. R. Explore ORCOSA Inc's employee directory with LeadIQ.

What industry does ORCOSA Inc belong to?

Minus sign iconPlus sign icon
ORCOSA Inc operates in the Biotechnology Research industry.

What technology does ORCOSA Inc use?

Minus sign iconPlus sign icon
ORCOSA Inc's tech stack includes Sucuri, Open Graph, WordPress, Shopify, Google Workspace, Google Cloud, jQuery and WP Engine.

What is ORCOSA Inc's email format?

Minus sign iconPlus sign icon
ORCOSA Inc's email format typically follows the pattern of FLast@orcosa.com. Find more ORCOSA Inc email formats with LeadIQ.

How much funding has ORCOSA Inc raised to date?

Minus sign iconPlus sign icon
As of November 2026, ORCOSA Inc has raised $11M in funding. The last funding round occurred on Jan 07, 2025 for $7.3M.

When was ORCOSA Inc founded?

Minus sign iconPlus sign icon
ORCOSA Inc was founded in 2020.
ORCOSA Inc logo

ORCOSA Inc

Biotechnology ResearchNew Jersey, United States11-50 Employees

Orcosa Inc is a biotechnology research company based in Ewing, New Jersey. It is developing the Rapid Infusion Technology Platform to enable fast-acting, easy-to-take formulations that improve drug absorption and patient outcomes. Its first product candidate, ORAVEXX, is a non-addictive cannabidiol composition that uses the RITe Platform to treat pain and offer an alternative to opioids. The company operates a cGMP-compliant manufacturing facility in the United States and collaborates with research institutions and physicians to support FDA-authorized investigator-initiated trials evaluating CBD for pain and inflammation.

Orcosa is a small to mid-sized life sciences company focused on advances in therapeutic delivery. In May 2026, the company announced leadership changes, naming Andy Drechsler as Chief Financial Officer and appointing a co-founder as Chief Executive Officer.

Section iconCompany Overview

Website
orcosa.com
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2020
Employees
11-50

Section iconFunding & Financials

  • $11M

    ORCOSA Inc has raised a total of $11M of funding over 2 rounds. Their latest funding round was raised on Jan 07, 2025 in the amount of $7.3M as a Venture Round.

  • $1M - $10M

    ORCOSA Inc's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.